Triple Negative Breast Cancer Diagnostics Market by Type of Test,, FISH Test, Blood Based Assay), Breast Biopsy)), by End user and Geography
Triple Negative Breast Cancer Diagnostics Market size was valued at US$ 11,401.2 million in 2021. It is expected to reach US$ 21.422.3 million by 2028, registering a CAGR of 10.09% over the forecast period 2022-2028. Breast cancer is characterized by the abnormal multiplication of the breast cells that will form lumps that may be nonmalignant or malignant in nature. Breast cancer is a heterogeneous disease disease that can be sub divided into clinical, histo pathological and molecular subtypes. TNBC accounts almost 15% of all breast cancer cases and is characterized by tumors that do not express estrogen receptor (ER), progesterone receptor (PR) or over express human epidermal growth factor receptor 2 (HER2). TNBC is associated with a poor prognosis and a high risk of distant recurrence and death with in first 3-5 years of follow up. TNBC diagnostics market is growing at significant rates owing to the rise in prevalence of the breast cancer According to GLOBOCAN 2012 data, breast cancer is the second most common cancer worldwide, accounting 11.9% cancer cases globally. An estimated, 1.7 million new cases were diagnosed in 2012. Companies operating in the global TNBC diagnostics market are focusing on the development of the new technologies to increase their market share. Furthermore, companies also adopting the acquisitions and mergers to strengthen their product portfolio and market position.
Study Period
2024-2030Base Year
2023CAGR
10.9%Largest Market
North AmericaFastest Growing Market
North AmericaThe advent of the novel technologies in breast cancer diagnosis and prevalence of the breast cancer worldwide are driving the breast lesion localization methods market. According to TNBC foundation TNBC occurs in about 10-20% of diagnosed breast cancers and is more likely to affect younger people, African Americans, Hispanics and the people with BRCA 1gene mutation. In 2012, 1.7 Mn women were diagnosed with breast cancer and among them 521900 women died because of it globally. In addition, increase in awareness about the early detection of breast cancer due to the different awareness campaigns and initiatives were taken by respective government and nonprofit organizations such as Canadian Breast Cancer Foundation, American Cancer Society, and World Health Organization (WHO) expected to boost the Triple Negative Breast Cancer Diagnostics market growth further. Moreover, favorable reimbursement policies in developed countries coupled with the rising demand for the better healthcare infrastructure globally projected to bolster the market growth over the forecast period. However, stringent regulatory approvals and high cost of the diagnosis, lack of awareness regarding TNBC anticipated to hamper the global market over the coming years.
Geographically, global Triple Negative Breast Cancer Diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America Triple Negative Breast Cancer Diagnostics is expected to grow at significant rates owing to lifestyle changes and the rise in the prevalence rates of breast cancer. Furthermore, established healthcare infrastructure and growing awareness related to the early detection of cancer are expected to boost the market growth in North America region. Europe market is projected to grow t high rates owing to the increase in incident rates of breast cancer and advancements in technology of diagnosis. According to the GLOBCON 2008 report by WHO, the incident rates of breast cancer is 89.7 per 100,000 women in Western Europe, which is highest incident rate in the world. Asia Pacific Triple Negative Breast Cancer Diagnostics market is expected to have lucrative growth opportunity due to developing healthcare infrastructure and rise in breast cancer cases. Furthermore, rise in disposable income, growing awareness regarding early detection of breast cancer
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market CAGR |
10.9% |
|
Test |
|
|
By End User |
|
Download Free Sample Report
The triple-negative breast cancer diagnostics market is projected to expand at a CAGR of 10.9% during the forecast period
Bio-Rad Laboratories, Inc, Biocept, Inc, Illumina, Inc, AstraZeneca plc, Epigenomics AG
North America is the fastest-growing region for the triple-negative breast cancer diagnostics market
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
